Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

589 ARTÍCULOS , VIENDO DEL 541 AL 555

A review of stem cell therapy: An emerging treatment for dementia in Alzheimer's and Parkinson's disease

Pradhan AU, Uwishema O, Onyeaka H, Adanur I, Dost B.

Brain Behav. 2022 Sep;12(9):e2740. doi: 10.1002/brb3.2740. Epub 2022 Aug 15.

Organ-On-A-Chip Models of the Blood-Brain Barrier: Recent Advances and Future Prospects

Kawakita S, Mandal K, Mou L, Mecwan MM, Zhu Y, Li S, Sharma S, Hernandez AL, Nguyen HT, Maity S, de Barros NR, Nakayama A, Bandaru P, Ahadian S, Kim HJ, Herculano RD, Holler E, Jucaud V, Dokmeci MR, Khademhosseini A.

Small. 2022 Sep;18(39):e2201401. doi: 10.1002/smll.202201401. Epub 2022 Aug 17.

Tacrine Derivatives in Neurological Disorders: Focus on Molecular Mechanisms and Neurotherapeutic Potential

Mitra S, Muni M, Shawon NJ, Das R, Emran TB, Sharma R, Chandran D, Islam F, Hossain MJ, Safi SZ, Sweilam SH.

Oxid Med Cell Longev. 2022 Aug 18;2022:7252882. doi: 10.1155/2022/7252882. eCollection 2022.

Pisa syndrome in dementia with Lewy bodies: A Chinese multicenter study

Su Z, Liu S, Chen G, Gan J, Bao X, Zhu H, Wang X, Wu H, Ji Y.

Parkinsonism Relat Disord. 2022 Oct;103:50-55. doi: 10.1016/j.parkreldis.2022.08.021. Epub 2022 Aug 24.

Recent Advancements in CNS Acting Drugs: A Step Towards End of Illness

Javed MN, Pottoo FH, Naim MJ, Chawla PA.

CNS Neurol Disord Drug Targets. 2022;21(10):882-883. doi: 10.2174/187152732110220722112205.

Cell models for Alzheimer's and Parkinson's disease: At the interface of biology and drug discovery

Cetin S, Knez D, Gobec S, Kos J, Pišlar A.

Biomed Pharmacother. 2022 May;149:112924. doi: 10.1016/j.biopha.2022.112924. Epub 2022 Apr 8.

Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature

Alhowail A, Alsikhan R, Alsaud M, Aldubayan M, Rabbani SI.

Drug Des Devel Ther. 2022 Aug 31;16:2919-2931. doi: 10.2147/DDDT.S367229. eCollection 2022.

Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease

Goyal A, Verma A, Dubey N, Raghav J, Agrawal A.

J Food Biochem. 2022 Dec;46(12):e14415. doi: 10.1111/jfbc.14415. Epub 2022 Sep 15.

Microglial ion channels: Key players in non-cell autonomous neurodegeneration

Sarkar S.

Neurobiol Dis. 2022 Nov;174:105861. doi: 10.1016/j.nbd.2022.105861. Epub 2022 Sep 14.

Hidden networks of aberrant protein transnitrosylation contribute to synapse loss in Alzheimer's disease

Lipton SA.

Free Radic Biol Med. 2022 Nov 20;193(Pt 1):171-176. doi: 10.1016/j.freeradbiomed.2022.10.272. Epub 2022 Oct 13.

Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder

Nakhal MM, Aburuz S, Sadek B, Akour A.

Molecules. 2022 Oct 23;27(21):7174. doi: 10.3390/molecules27217174.

Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment

Kopp KO, Glotfelty EJ, Li Y, Greig NH.

Pharmacol Res. 2022 Dec;186:106550. doi: 10.1016/j.phrs.2022.106550. Epub 2022 Nov 11.

Resolvins Lipid Mediators: Potential Therapeutic Targets in Alzheimer and Parkinson Disease

Anand S, Azam Ansari M, Kumaraswamy Sukrutha S, Alomary MN, Anwar Khan A, Elderdery AY.

Neuroscience. 2022 Dec 15;507:139-148. doi: 10.1016/j.neuroscience.2022.11.001. Epub 2022 Nov 11.

[Role of β2-Adrenergic Receptor Agonist in the Cognitive Impairment Associated with Neurodegenerative Diseases]

Wang ZJ, Guo WN, Guo QZ, Wang S, Wang TJ.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2022 Dec;44(6):1112-1116. doi: 10.3881/j.issn.1000-503X.14469.

Applications of nanobodies in brain diseases

Zheng F, Pang Y, Li L, Pang Y, Zhang J, Wang X, Raes G.

Front Immunol. 2022 Nov 8;13:978513. doi: 10.3389/fimmu.2022.978513. eCollection 2022.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias